Roche gains RoActemra European Approval for children with RA
Roche has gained approval in Europe for its biologic RoActemra for systemic juvenile idiopathic arthritis. The European Commission has approved the use of RoActemra (tocilizumab) for the treatment of active sJIA in patients two years of age and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs and systemic corticosteroids (used to